Paladin Labs Announces the Canadian Launch of Abstral(R)

Paladin Labs Announces the Canadian Launch of Abstral(R) 
MONTREAL, CANADA -- (Marketwire) -- 06/14/11 --   Paladin labs Inc.
(TSX: PLB), a leading Canadian specialty Pharmaceutical company,
announced today the launch of Abstral(R) (fentanyl citrate sublingual
tablet). Abstral(R) is a novel, rapidly-disintegrating, sublingual
(under the tongue) formulation of fentanyl, a well-established opioid
used for the management of breakthrough pain for cancer patients
already receiving, and tolerant to opioid analgesics for chronic
pain. Abstral(R) will complement Paladin's growing pain franchise
which includes Tridural(R), Metadol(R) and Pennsaid(R).  
"Though officially launching today, Abstral(R) has been available to
patients and their physicians in Canada for almost 2 months under our
compassionate early use program", said Jonathan Ross Goodman,
President and CEO of Paladin Labs. "This early experience program
with Abstral(R) has seen meaningful and heart-warming quality of life
improvements in many patients taking our product. The importance of
this quality of life improvement to patients, their families and care
givers should not be underestimated and gives us confidence as we now
transition into the full commercial launch phase of this important
new product."  
Paladin obtained the Canadian rights from ProStrakan Group plc
("ProStrakan"), a wholly owned subsidiary of Kyowa Hakko Kirin Co.,
Ltd., (TSE: 4151) in December 2008 and was granted Canadian
regulatory approval in February 2011. 
About Abstral(R)  
Abstral(R) is a fast-acting and rapidly disintegrating tablet for
sublingual administration of fentanyl intended for the management of
breakthrough pain in cancer patients who are already receiving, and
tolerant to opioid analgesics for their underlying persistent cancer
pain.  
Abstral(R) is already marketed by ProStrakan across the principal
European markets. In the top four European markets, Abstral(R)
achieved a 24% market share by tablet volume of short-acting fentanyl
products (Source: IMS data June 2010).  
About Breakthrough Cancer Pain  
Breakthrough cancer pain ("BTP") is defined as rapid onset and short
duration exacerbations of severe pain experienced by patients who
have relatively stable and adequately controlled baseline pain.(1) It
is known as BTP because it "breaks through" a regular pain medicine
schedule. For some patients, BTP occurs during certain everyday
activities, such as walking or dressing. For others, it occurs
unexpectedly without any apparent cause. Between 64% to 89% of
patients with cancer experience BTP and they average 4 to 7 episodes
per day. (2)  
In a recent survey of patients with cancer related BTP(3):  
89% stated that BTP negatively affected their quality of life  
73% stated that BTP wakes them from a deep sleep at least once a
month  
76% stated that BTP affects their ability to perform everyday
household chores  
75% stated that BTP is one of the most challenging effects of having
cancer  
35% stated that BTP affects their relationships with their family
members  
82% stated that BTP negatively affects their emotional health  
About Paladin Labs Inc.  
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty
pharmaceutical company focused on acquiring or in-licensing
innovative pharmaceutical products for the Canadian market. With this
strategy, a focused national sales team and proven marketing
expertise, Paladin has evolved into one of Canada's leading specialty
pharmaceutical companies. Paladin's shares trade on the Toronto Stock
Exchange under the symbol PLB. For more information about Paladin,
please visit the Company's web site at www.paladinlabs.com. 
This press release may contain forward-looking statements and
predictions. These forward-looking statements, by their nature,
necessarily involve risks and uncertainties that could cause actual
results to differ materially from those contemplated by the
forward-looking statements. The Company considers the assumptions on
which these forward-looking statements are based to be reasonable at
the time they were prepared, but cautions that these assumptions
regarding the future events, many of which are beyond the control of
the Company and its subsidiary, may ultimately prove to be incorrect.
Factors and risks, which could cause actual results to differ
materially from current expectations, are discussed in the annual
report as well as in the Company's Annual Information Form for the
year ended December 31, 2010. The Company disclaims any intention or
obligation to update or revise any forward-looking statements whether
as a result of new information or future events and except as
required by law. For additional information on risks and
uncertainties relating to these forward-looking statements, investors
should consult the Company's ongoing quarterly fillings, annual
report and Annual Information Form and other fillings found on SEDAR
at www.sedar.com.  
(1) Portenoy RK, Hagen NA. Pain 1990; 41: 273-281 
(2) Portenoy RK et al. Pain 1999; 81(1-2):129-134 
(3) The American Pain Foundation. Breakthrough Cancer Pain Survey
Fact Sheet 
Contacts:
Samira Sakhia
Chief Financial Officer
Paladin Labs Inc.
514-669-5367
514-344-4675 (FAX)
info@paladinlabs.com
www.paladinlabs.com
 
 
Press spacebar to pause and continue. Press esc to stop.